Bio-Techne Corp (TECH)
Quick ratio
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | US$ in thousands | 162,186 | 140,670 | 177,549 | 187,540 | 151,791 | 139,915 | 130,132 | 148,663 | 180,571 | 127,282 | 164,682 | 165,257 | 172,567 | 160,821 | 211,845 | 196,321 | 199,091 | 186,136 | 165,526 | 169,404 |
Short-term investments | US$ in thousands | 0 | 0 | 0 | 0 | 1,072 | 5,397 | 5,520 | 0 | 23,739 | 29,915 | 32,074 | 37,818 | 74,462 | 70,351 | 67,135 | 38,740 | 32,463 | 90,108 | 117,426 | 117,986 |
Receivables | US$ in thousands | 206,876 | 237,140 | 217,940 | 223,688 | 241,394 | 227,887 | 207,451 | 204,570 | 218,468 | 216,415 | 184,763 | 174,174 | 194,548 | 202,095 | 152,896 | 147,548 | 145,385 | 157,790 | 128,243 | 122,635 |
Total current liabilities | US$ in thousands | 175,849 | 169,204 | 161,256 | 142,128 | 159,379 | 149,820 | 135,231 | 127,754 | 128,509 | 141,163 | 128,395 | 137,629 | 176,018 | 166,838 | 154,809 | 133,992 | 152,284 | 137,640 | 117,568 | 105,424 |
Quick ratio | 2.10 | 2.23 | 2.45 | 2.89 | 2.47 | 2.49 | 2.54 | 2.76 | 3.29 | 2.65 | 2.97 | 2.74 | 2.51 | 2.60 | 2.79 | 2.86 | 2.48 | 3.15 | 3.50 | 3.89 |
June 30, 2025 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($162,186K
+ $0K
+ $206,876K)
÷ $175,849K
= 2.10
The analysis of Bio-Techne Corp’s quick ratio over the specified period reveals a generally stable liquidity position, with fluctuations indicating moderate variations in the company's ability to meet short-term obligations using its most liquid assets.
Beginning with a high quick ratio of 3.89 as of September 30, 2020, the figure demonstrates that the company's liquid assets significantly exceeded current liabilities at that point, suggesting robust short-term solvency. Over the subsequent quarters, there was a gradual decline, reaching a low of 2.48 on June 30, 2021, which still indicates a strong liquidity buffer, albeit less pronounced than in 2020.
Following this dip, the quick ratio experienced some fluctuations, with a slight increase to 2.86 as of September 30, 2021, and remaining relatively stable through December 2021 and March 2022, hovering between approximately 2.60 and 2.97. This stability suggests consistent management of liquid assets relative to short-term liabilities during this period.
From mid-2022 onward, a trend of gradual decline becomes apparent, with the ratio decreasing from 2.51 on June 30, 2022, to around 2.23 by March 31, 2025. Notably, there are intermittent periods of slight recovery; for example, the ratio rose to 3.29 on June 30, 2023, but then declined again to 2.76 by September 30, 2023, and further to 2.45 by December 31, 2024. The recent data indicates that although the quick ratio has decreased over time, it remains above 2.0 in most periods, maintaining a generally healthy liquidity posture.
Overall, despite the declining trend from its peak in late 2020 and mid-2023, the quick ratio consistently remains above 2.0 throughout the analyzed period, which signifies that Bio-Techne Corp maintains sufficient liquid assets to cover its immediate liabilities. The decrease over time suggests a potential shift in liquidity management or changes in the composition of liquid assets relative to liabilities, but the ratios still reflect a position of liquidity adequacy rather than concerning short-term solvency issues.
Peer comparison
Jun 30, 2025